Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management

This article offers an overview of ADHD, an overview of both stimulant and non-stimulant medication options as well an overview of stimulant misuse. It explores the medication mechanisms of action and side effect profiles, as well as offering an in-depth summary of the novel agents recently approved and soon to-be approved for use in youth. PubMed and Medline were utilized. Search terms included children, adolescents, ADHD and medication. FDA package inserts were reviewed for all medications.EXPERT OPINION: New formulations of medications include an evening administered, extended, and delayed-release form of methylphenidate (DR/ER MPH) a methylphenidate pro-drug (serdexmethylphenidate) and an amphetamine patch. The availability of a new SNRI (selective norepinephrine reuptake inhibitor), viloxazine-extended release (VER) and the pending approval of a triple reuptake inhibitor (centanafadine) provide welcome additions to the prescriber's toolbox.PMID:37587841 | DOI:10.1080/17512433.2023.2249414
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research